Shares of First Tracks Biotherapeutics (NASDAQ:TRAX – Get Free Report) have been assigned a consensus rating of “Buy” from the nine brokerages that are covering the company, MarketBeat reports. One analyst has rated the stock with a hold recommendation, seven have given a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $38.25.
A number of research firms have weighed in on TRAX. Barclays began coverage on shares of First Tracks Biotherapeutics in a research note on Wednesday, April 22nd. They issued an “overweight” rating and a $40.00 target price on the stock. Leerink Partners began coverage on shares of First Tracks Biotherapeutics in a research note on Friday, April 24th. They issued an “outperform” rating and a $46.00 target price on the stock. HC Wainwright began coverage on shares of First Tracks Biotherapeutics in a research note on Tuesday, April 28th. They issued a “buy” rating and a $30.00 target price on the stock. Wedbush began coverage on shares of First Tracks Biotherapeutics in a research note on Friday, April 24th. They issued an “outperform” rating and a $30.00 target price on the stock. Finally, UBS Group began coverage on shares of First Tracks Biotherapeutics in a research note on Tuesday, April 21st. They issued a “buy” rating and a $45.00 target price on the stock.
Get Our Latest Research Report on First Tracks Biotherapeutics
First Tracks Biotherapeutics Stock Down 4.1%
Featured Articles
- Five stocks we like better than First Tracks Biotherapeutics
- Gravity Check: Houston, SpaceX Has a Valuation Problem
- Strategy’s Bitcoin Rally Has a Hidden Engine
- Okta’s AI Moment May Be Bigger Than Investors Realize
- 3 Rate-Ready Stocks for the New Fed Chair’s First Big Test
Receive News & Ratings for First Tracks Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for First Tracks Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
